Boston Scientific Commences (AVANT GUARD) Study of Farapulse Pulsed Field Ablation System as a 1L Treatment for Persistent Atrial Fibrillation (AF)
Shots:
- The AVANT GUARD study will assess the safety and efficacy of the Farapulse PFA System in patients (n= >500) with persistent AF randomized to undergo pulmonary vein isolation (PVI) and left atrial posterior wall ablation using the System or receive AAD treatment for 3yrs. The trial will compare outcomes, incl. device or procedure-related AEs, freedom from AF, atrial flutter, or atrial tachycardia rates, and AF burden measurement
- The participants will receive the LUX-Dx Insertable Cardiac Monitor alongside treatment for easy monitoring, capturing and transmitting arrhythmia data, facilitating continuous rhythm monitoring
- The company plans the US FDA approval of the FARAPULSE PFA System in the Q1’24
Ref: Boston Scientific | Image: Boston Scientific
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
